Head-to-head · WeighScore
Aurelius Health Group vs GOAL.MD
The verdict
GOAL.MD takes it — 68.6/100 to 60.8/100.
GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aurelius Health Group | GOAL.MD |
|---|---|---|
| WeighScore | 60.8/100 | 68.6/100 |
| Grade | C | C |
| Scorecard rank | #311 | #142 |
| Semaglutide | Not disclosed | $179/mo |
| Tirzepatide | $199/mo (microdose tier, compounded) | $249/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #311 · C
Strengths
- Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
- LegitScript Certified
- Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
- Unusually candid about the limited evidence base for microdosing
Where it loses points
- The advertised $89 is a first-month new-patient rate; every month after it is $199
- This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
- No state count is published, only 'most US states', confirmed at intake
- The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
- Compounded tirzepatide is not an FDA-approved finished product
Graded #142 · C
Strengths
- Transparent dose-tiered pricing on brand pens
- LegitScript Certified
- Manual-renewal model — no surprise auto-billing
- Free nutrition coach included
- BBB A+ rating since 2021
Where it loses points
- No named compounding pharmacy partner
- Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
- No URAC or PCAB pharmacy accreditation
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.